According to the study, published in the American Journal of Roentgenology, imaging metrics associated with OS and pathologic responses in PDA could help in guiding clinical management outcomes for PDA patients receiving emergent therapeutic interventions. Read more . . .
Post neoadjuvant therapy (NAT)changes in metabolic metrics tracked on PET/MRI and pathologic responses from CT were associated with pathologic responses and overall survival (OS) for pancreatic ductal adenocarcinoma (PDA) patients, suggests a recent study.